Alpha-1 antitrypsin (AAT) is the major circulating serum antiprotease, with normal plasma levels ranging from 11 to 30 microMolar. Approximately 4% of the North American and Northern European populations possess at least one copy of a mutant allele, known as Pi*Z, which results from a single amino acid substitution of Lys for Glu at position 342. In the homozygous state (Pi*ZZ), this mutation leads to severe deficiency of AAT and can result in liver disease which is due to a toxic gain-of-function of the Z-AAT mutant protein. Accumulation of Z- AAT polymers within hepatocytes consistently results in a state of serum AAT deficiency due to inefficient secretion. Two hundred thousand is a conservative estimate of the number of ZZ patients in the western world; however, there is currently no cure for the lung or liver disease. Protein replacement is given by intravenous infusion, with the approved dosing regimen being weekly infusions, and the only alternative dosing with proven equivalence being every-other-week infusions. Thus, gene augmentation with normal (PiM) AAT delivered via recombinant adeno- associated viral (rAAV) vectors has been developed as a potential alternative for ?sustained release? of the therapeutic protein. We believe that in order to safely augment AAT from Z-AAT patient livers it may be necessary to silence the endogenous Z-AAT to prevent overwhelming the already stressed hepatocyte. Preliminary data in PiZ transgenic mice suggest that expressing rAAV-derived AAT without first silencing the endogenous Z-AAT can be hepatotoxic. Thus, this project aims to clinically translate a therapeutic strategy that combines traditional gene therapy with RNAi therapeutics in a single rAAV vector approach. We have termed these as dual-function rAAV vectors, and we have engineered them as a ?liver- sparing? approach to target the burdened livers of PiZ AATD patients. Proof-of-concept studies in PiZ mice, confirmed that the dual function vector reduced misfolded AAT and concomitantly augmented serum levels of the normal protein. We hypothesize that endogenous Z-AAT silencing and M-AAT augmentation is feasible and a safe therapeutic approach for treating alpha-1 antitrypsin deficiency. We will test this hypothesis with the following three aims.
In aim 1 we will optimize the dual function expression cassette for maximum knockdown and augmentation efficiency. These vectors will then be modified with non- human primate sequences (NHP) for aim 2, where we will assess efficacy of the dual function vector in non- human primates.
In aim 3 we will perform a formal GLP pharm/tox and biodistribution study with the clinical version of the vector to prepare for an investigational new drug application with the FDA. Finally aim 4 will investigate the safety of peripheral intravenous delivery of these vectors in patients with alpha-1 antitrypsin deficiency.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL131471-05
Application #
9935133
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Postow, Lisa
Project Start
Project End
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Type
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Ibraheim, Raed; Song, Chun-Qing; Mir, Aamir et al. (2018) All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. Genome Biol 19:137
Wang, Dan; Li, Jia; Song, Chun-Qing et al. (2018) Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. Nat Biotechnol 36:839-842
Smith, Jordan L; Mou, Haiwei; Xue, Wen (2018) Understanding and repurposing CRISPR-mediated alternative splicing. Genome Biol 19:184
Yoon, Yeonsoo; Wang, Dan; Tai, Phillip W L et al. (2018) Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses. Nat Commun 9:412
Song, Chun-Qing; Xue, Wen (2018) CRISPR-Cas-related technologies in basic and translational liver research. Nat Rev Gastroenterol Hepatol 15:251-252
Zhang, Wei; Li, Linjing; Su, Qin et al. (2018) Gene Therapy Using a miniCEP290 Fragment Delays Photoreceptor Degeneration in a Mouse Model of Leber Congenital Amaurosis. Hum Gene Ther 29:42-50
Tai, Phillip W L; Xie, Jun; Fong, Kaiyuen et al. (2018) Adeno-associated Virus Genome Population Sequencing Achieves Full Vector Genome Resolution and Reveals Human-Vector Chimeras. Mol Ther Methods Clin Dev 9:130-141
Borel, Florie; Sun, Huaming; Zieger, Marina et al. (2018) Editing out five Serpina1 paralogs to create a mouse model of genetic emphysema. Proc Natl Acad Sci U S A 115:2788-2793
Zhang, Xiao-Ou; Fu, Yu; Mou, Haiwei et al. (2018) The temporal landscape of recursive splicing during Pol II transcription elongation in human cells. PLoS Genet 14:e1007579
Wang, Dan; Gao, Guangping (2018) Taking a Hint from Structural Biology: To Better Understand AAV Transport across the BBB. Mol Ther 26:336-338

Showing the most recent 10 out of 42 publications